Résonance magnétique cardiaque (RMC) c’est une technique sans rayonnement, qui est considérée comme l’étalon-or pour l’évaluation de l’anatomie cardiaque, de la fonction et même de la composition des tissus. L’essai RESILIENCE utilisera la RMC comme principale méthodologie de mesure des résultats, et les patients inscrits à l’essai subiront 3 examens pendant toute la durée de l’étude.
Essai clinique multinational, prospectif, de preuve de concept de phase II, à double insu, contrôlé par simulation, randomisé (ECR) pour évaluer l’efficacité et l’innocuité du préconditionnement ischémique distal (RIC) chez les patients atteints de Lymphome recevant des anthracyclines. Les patients devant subir ≥5 cycles de chimiothérapie seront éligibles.
Clinical trials are essential for advancing medicine. Thanks to them, today we now have safer, more effective, and increasingly personalized treatments. However, for many people, participating in a clinical trial naturally raises questions: What does participation involve? How does the process unfold? What kind of follow‑up is provided? At RESILIENCE,
Early detection of cardiac damage is one of the most effective tools to prevent cardiovascular complications, improve prognosis, and preserve quality of life. Identifying alterations in the heart before symptoms appear allows for early intervention, treatment adjustments, and protection of cardiovascular health in both the short and long term. This
December arrives each year with the perfect blend of excitement, celebrations, and long-awaited reunions. These are days to share, enjoy, and create memories with those we love most. At the same time, it is also a season when our habits tend to change: richer meals, more alcohol than usual, less
Autumn brings shorter days, cooler temperatures that invite for warm clothing, and a routine that sometimes sets the pace again. This season often fosters a sense of tranquility; however, it may also be accompanied by increased fatigue, emotional fluctuations, or elevated stress levels. For those going through an oncological process,
Cardiovascular research has just taken a huge step forward. The REBOOT clinical trial, led by the Spanish National Center for Cardiovascular Research (CNIC) in collaboration with the Mario Negri Institute in Milan, has shown that a medical practice in place for more than 40 years may no longer be necessary
Cancer, along with cardiovascular diseases, is among the leading causes of mortality worldwide. In Spain, it ranks first in both incidence and number of deaths. However, it is estimated that only between 5% and 10% of cases are genetic or hereditary. The remaining cases are associated with environmental factors and
